[心不全の診断と治療]
Samira Soltani, Johann Bauersachs1
1Klinik für Kardiologie und Angiologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland. bauersachs.johann@mh-hannover.de.
Herz
|August 25, 2025
まとめ
SGLT2 阻害剤や GLP-1 アナログのような新しい治療法は,保存されたエジェクション分数 (HFpEF) の心不全の予後を改善しています. フィネレノンと弁の介入は,HFpEF患者にとっても有望である.
科学分野:
- 心臓病科
- 薬理学について
背景:
- 保存されたエジェクション分数 (HFpEF) の心不全の管理は,伝統的に利尿薬による症状緩和に焦点を当てています.
- 現在のガイドラインは,EMPEROR-PreservedとDELIVERの研究によって支持された,HFpEFの改善のためのナトリウム-グルコース関連トランスポーター2 (SGLT2) 阻害剤を推奨しています.
研究 の 目的:
- 保存されたエジェクション分数 (HFpEF) による心不全の現在の治療戦略と新たな治療戦略をレビューする.
- HFpEFにおけるSGLT2阻害剤,フィネレノン,GLP-1類似剤,および弁性吐に対する介入の予後効果を強調する.
主な方法:
- EMPEROR-Preserved,DELIVER,FINEARTS-HF,STEP-HFpEF,SUMMITを含む主要な臨床試験について
- HFpEF患者における心血管のアウトカム,入院,生活の質,症状の負担に対する治療効果の分析.
主要な成果:
- SGLT2阻害剤は,HFpEFの予後を改善するためにクラスIの推奨を示しています.
- フィネレノンは,FINEARTS- HF研究において,心血管疾患による死亡/ 入院に良い効果を示した.
- GLP- 1 アナログ (STEP- HFpEF,SUMMIT) は,肥満のHFpEF患者の生活の質と心不全のイベントを改善しました.
- 重度のミトラ弁および三弁の吐治療は,症状の負担,入院,および予後に影響します.
結論:
- SGLT2阻害剤は,HFpEFの予後のための基石療法です.
- ファイネレノンとGLP-1類型を含む新興治療法は,特に特定の患者のサブグループで,HFpEF管理のための新しい道を提供します.
- バルブ性心疾患の治療は,総合的なHFpEF治療に不可欠です.
関連する概念動画
01:30Heart Failure IV: Classification and Diagnostic Evaluation
32
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
32
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:22Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
01:30Heart Failure VII: Nursing Interventions
139
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
139
01:29Cardiomyopathy V: Interprofessional Care
33
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
33
01:17Pathophysiology of Heart Failure
1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K